Lyra Therapeutics, INC

Lyra Therapeutics has entered into an agreement to terminate its sublease at 880 Winter Street, Waltham, for a $2.1 million payment.

Lyra Therapeutics has terminated its leases for facilities in Watertown and Waltham, Massachusetts, incurring significant termination fees and forfeiting security deposits.

Lyra Therapeutics, Inc. announced its common stock will be suspended from trading on Nasdaq following the withdrawal of its delisting appeal.

Lyra Therapeutics, Inc. received a notice of default for $484,431.92 in unpaid rent as it continues preparations for a wind-down of operations.

Lyra Therapeutics received a delisting notice from Nasdaq, citing its status as a public shell and non-compliance with stockholders' equity requirements, prompting an appeal.

Lyra Therapeutics announced the suspension of its lead product candidate LYR-210 development and a significant workforce reduction to preserve capital while exploring strategic alternatives.

Lyra Therapeutics reports substantial doubt about its ability to continue as a going concern, despite positive Phase 3 ENLIGHTEN 2 trial results, following a major workforce reduction and a prior trial failure.

Lyra Therapeutics reported positive Phase 3 ENLIGHTEN 2 trial results for LYR-210, significantly reducing its net loss in Q2 2025 while addressing going concern doubts and securing new financing.

Lyra Therapeutics faces going concern doubts as it reports Q1 2025 results following a restructuring and strategic review after a failed Phase 3 trial.

Lyra Therapeutics' Phase 3 ENLIGHTEN 1 trial for LYR-210 failed to meet its primary endpoint, leading to a significant restructuring and workforce reduction.

Lyra Therapeutics' Phase 3 ENLIGHTEN 1 trial for LYR-210 failed to meet its primary endpoint, leading to a significant restructuring and workforce reduction.

Lyra Therapeutics reports a net loss of $22.45 million for the first quarter of 2024, while continuing to advance its clinical programs.

Lyra Therapeutics, a clinical-stage biotech, announced the suspension of its lead drug candidate LYR-210 development, a significant workforce reduction, and its delisting from Nasdaq, as it explores strategic alternatives amidst substantial financial losses.

Lyra Therapeutics' future hangs in the balance as it seeks strategic alternatives following a failed Phase 3 trial, workforce reduction, and ongoing financial challenges.

Lyra Therapeutics' 10-K filing details its capital structure, shareholder rights, and corporate governance policies, alongside updates on its clinical programs.

Director W. Bradford Smith has disposed of his entire beneficial ownership stake in Lyra Therapeutics, Inc.

Maria Palasis, a Director and Officer at Lyra Therapeutics, reported a transaction involving 2,000 shares of common stock on April 1, 2026.

Jason Cavalier, Principal Financial Officer at Lyra Therapeutics, Inc., reported a transaction involving 667 shares of common stock on April 1, 2026.

Lyra Therapeutics' Chief Financial Officer, Jason Cavalier, sold 769 shares of common stock on January 6, 2026, to cover tax liabilities from RSU vesting.

Lyra Therapeutics President & CEO Maria Palasis sold 1,702 shares of common stock to cover tax obligations related to RSU vesting, as per a pre-arranged 10b5-1 plan.

Perceptive Advisors and related entities reported the sale of Lyra Therapeutics common stock in mid-November 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Lyra Therapeutics hires Alliance Advisors to assist with proxy solicitation for its 2025 Annual Meeting of Stockholders.

Lyra Therapeutics' upcoming annual meeting on May 14, 2025, includes proposals for director elections, auditor ratification, and a potential reverse stock split.

Lyra Therapeutics is asking stockholders to approve a reverse stock split proposal at its upcoming annual meeting to maintain its Nasdaq listing and potentially facilitate future capital raising.

Lyra Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with voting open until June 12, 2024, covering director elections, auditor ratification, and officer exculpation.

Lyra Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on director elections, auditor ratification, and an amendment to the company's Restated Certificate of Incorporation.

Lyra Therapeutics has filed an S-1 registration statement to allow selling securityholders to resell up to 846,744 shares of common stock, following a recent private placement and the announcement of mixed Phase 3 clinical trial results for its lead product candidate, LYR-210.

Perceptive Advisors and its affiliates have fully divested their beneficial ownership in Lyra Therapeutics, Inc., ceasing to be a 5% shareholder.

Perceptive Advisors and its affiliates have reduced their beneficial ownership in Lyra Therapeutics, Inc. to 5.5% through recent share sales.

Perceptive Advisors and its affiliates have reduced their beneficial ownership in Lyra Therapeutics, Inc. to 7.8% through recent share sales.

Perceptive Advisors and its affiliates have significantly reduced their beneficial ownership in Lyra Therapeutics, Inc. to 11.2% through recent share sales.

Perceptive Advisors and affiliates updated their beneficial ownership in Lyra Therapeutics, Inc., now holding 15.55% of common stock.

Sabby Management, LLC and affiliated entities reported a 9.9% beneficial ownership stake in Lyra Therapeutics, Inc. common stock.

Citadel and its affiliated entities have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 0.0% in Lyra Therapeutics, Inc. as of December 31, 2024.